IL-18 is a pro-inflammatory cytokine that triggers IFN-γ production and increases T- and NK-cell activity. IL-18’s effects are blocked by IL-18 binding protein (IL-18BP), an endogenous protein that binds to IL-18 with high affinity and that is highly present in the tumor microenvironment (TME).
There is still a lack of specific biomarkers in biliary epithelial cells of patients with primary sclerosing cholangitis (PSC). Investigators from the...
By analyzing a cohort of adolescents that developed myocarditis or pericarditis after vaccination against SARS-CoV-2 vaccination, researchers from Yale University School of Medicine were able to pinpoint the underlying mechanism as an overly active innate immune response to the vaccine that led to broad activation of T cells and natural killer (NK) cells. Myocarditis “has been seen in other vaccine contexts, though is most common after viral infection,” Carrie Lucas told reporters at a press conference announcing the findings.
One way to prevent the effect of a molecule is to use the cell’s own machinery to break it down. This is what the PROTAC technology does, an acronym for proteolysis targeting chimera, or BacPROTAC, when applied to bacteria. A study led by Austrian and German scientists has demonstrated the effectiveness of this technique in eliminating the tuberculosis pathogen Mycobacterium tuberculosis (Mtb). The finding opens the door to the BacPROTAC strategy as an alternative to the development of drugs against this microorganism.
Jiangsu Chia Tai Tianqing Pharmaceutical Group Co. Ltd. and Medshine Discovery Inc. have jointly patented pyrimidine tricyclic derivative soluble guanylate cyclase (sGC) activators. They are reported to be useful for the treatment of heart failure and hypertension.
Biosplice Therapeutics Inc. has prepared and tested pyrrolo[2,1-F][1,2,4]triazines derivatives acting as dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) inhibitors and reported to be useful for the treatment of cancer, diabetes and neurological disorders.
Research at Vasa Therapeutics Sp zoo has led to the identification of diazabicyclooctane derivatives acting as matrix metalloproteinase (MMP) inhibitors and thus reported to be useful for the treatment of heart failure.
RSS
